Clinical Trials on Siewert Type II Adenocarcinoma of Esophagogastric Junction in South Africa

Total 140 results

NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma... and other conditions

United States
National Cancer Institute (NCI)

Suspended

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Esophageal Adenocarcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Gastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IVA Esophageal Adenocarcinoma... and other conditions

United States
Imugene Limited

Active, not recruiting

A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) (nextHERIZON)

Stomach Cancer | Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Cancer of Stomach | Stomach Adenocarcinoma

Taiwan, Australia
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma...

United States
Bristol-Myers Squibb

Completed

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Gastric Cancer | Esophagogastric Junction | Cancer of the Stomach

United States, Germany, Italy, Argentina, Australia, Belgium, France, Poland, Puerto Rico, Spain, Czechia, Austria, Canada, United Kingdom, Chile, Norway, Singapore
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

United States, Spain, Italy, Australia, Russian Federation, Taiwan, Korea, Republic of, Thailand, Canada, Turkey, Germany, Romania, United Kingdom, Hungary, Brazil, France, Japan
Medical University of South Carolina

Terminated

Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma

Adenocarcinoma of Head of Pancreas

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Gastric Cancer | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States, Puerto Rico
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Amgen

Completed

Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Recurrent Gastric Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Diffuse Gastric Adenocarcinoma | Gastric Intestinal Type Adenocarcinoma | Gastric Mixed Adenocarcinoma

United States, Canada
MedImmune LLC

Completed

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma

Canada, United States, Taiwan, Korea, Republic of, Japan, Singapore
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)

Gastric Cancer | Esophageal Adenocarcinoma | Gastroesophageal Junction Cancer

United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Si... and more
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma (ILUSTRO)

Gastric Cancer | Pharmacokinetics of Zolbetuximab | Gastro-esophageal Junction (GEJ) Cancer | Pharmacokinetics of Oxaliplatin | Pharmacokinetics of Fluorouracil Bolus (5-FU)

United States, Italy, Japan, Korea, Republic of, Taiwan, France
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Stage II Prostate Adenocarcinoma

United States, Canada, Hong Kong, Switzerland, India, Ireland
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
Morphotek

Completed

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Adenocarcinoma of the Lung

Spain, United States, Australia, Canada, Germany, Italy, Poland, Russian Federation
Tarveda Therapeutics

Recruiting

PEN-866 in Patients With Advanced Solid Malignancies

Neoplasms | Carcinoma | Small Cell Lung Carcinoma | Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor | Gastric Adenocarcinoma | Small-cell Lung Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma | Adenocarcinoma of the Pancreas | Endometrial Adenocarcinoma | Squamous Cell Carcinoma of the Penis | Gastroesophageal... and other conditions

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE)

Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Gilead Sciences

Completed

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Spain, United States, Hungary, United Kingdom, Italy, France, Poland, Australia, Belgium
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States, Canada, Puerto Rico
Hoffmann-La Roche
BioLineRx, Ltd.; Halozyme Therapeutics

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

United States, United Kingdom, Australia, Korea, Republic of, Taiwan, Israel, Spain
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Sky Foundation

Active, not recruiting

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

Pancreatic Adenocarcinoma | Borderline Resectable Adenocarcinoma of the Head of the Pancrease

United States, Canada
Bristol-Myers Squibb

Withdrawn

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stomach Cancer | Gastric Cancer | Cancer of the Stomach | Gastroesophageal Junction

Brazil, Italy, United States, Argentina, Chile, Germany, Spain, Australia, Canada, Portugal, Mexico, Romania, Colombia, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Recurrent Esophageal Carcinoma | Recurrent Gastric Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Carcinoma | Metastatic Gastric Carcinoma | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer... and other conditions

United States
LIB Therapeutics LLC
Medpace, Inc.

Enrolling by invitation

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (LIBerate-OLE)

Familial Hypercholesterolemia | Elevated Cholesterol | Cardiovascular Disease With Mention of Arteriosclerosis

United States, Israel, Norway, South Africa, Turkey, India
Sidney Kimmel Comprehensive Cancer Center at Johns...
Greater Washington Community Foundation

Terminated

Muscadine Plus (MPX) In Men With Prostate Cancer

Adenocarcinoma of the Prostate

United States
Medical University of South Carolina

Terminated

Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma

Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II

United States
Boehringer Ingelheim

Completed

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Lung Neoplasms

Hong Kong, Korea, Republic of, Spain, Singapore, China, United Kingdom, Taiwan, Canada, Australia, Germany, Ireland, Sweden, France, Norway
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Prostate Adenocarcinoma | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma

United States, Canada, Switzerland
Amgen
Zai Lab (China only)

Recruiting

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Canada, Japan, United States, Korea, Republic of, China, Italy, Australia, Sweden, Spain, Taiwan, France, Belgium, Denmark, Thailand, Turkey, Czechia, Bulgaria, Brazil, Norway, Mexico, Poland, Estonia, Israel, Greece, Romania, Chile, Peru, Po... and more
Trans Tasman Radiation Oncology Group
Australasian Gastro-Intestinal Trials Group; Colorectal Surgical Society of... and other collaborators

Completed

A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum

Adenocarcinoma of Rectum

Australia, New Zealand
Amgen

Recruiting

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Israel, Italy, Spain, Switzerland, Australia, Germany, United Kingdom, Austria, France, Japan, Taiwan, China, Belgium, Poland, Thailand, Canada, Czechia, Singapore, Hungary, Argentina, Brazil, Romania, Portuga... and more
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
Dendreon
PRA Health Sciences

Active, not recruiting

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (ProVent)

Adenocarcinoma of the Prostate

United States
Panbela Therapeutics, Inc.

Completed

Study of SBP-101 in Pancreatic Cancer

Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

United States, Australia
Multitude Therapeutics Inc.
Tigermed Consulting Co., Ltd

Recruiting

AMT-151 in Patients With Selected Advanced Solid Tumours

Ovarian Cancer | Ovarian Epithelial Cancer | Lung Adenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Endometrial Cancer | Advanced Cancer | Ovarian Clear Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial... and other conditions

China, Australia
Avelas Biosciences, Inc.
Clinipace Worldwide; RRD International, Inc.

Completed

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Carcinoma, Ductal, Breast | Breast Cancer Female | Stage III Breast Cancer | Carcinoma Breast | Primary Invasive Malignant Neoplasm of Female Breast

United States
OncoC4, Inc.
Avance Clinical; OncoC4 AU Pty Ltd

Recruiting

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (PRESERVE-009)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Fallopian Tube Cancer | Non Small Cell Lung Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Primary Peritoneal... and other conditions

Australia
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

Advanced Colorectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the Colon

United States, Australia, Belgium, Brazil, Canada, Czech Republic, Greece, Korea, Republic of, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain
Ipsen

Active, not recruiting

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)

Metastatic Adenocarcinoma of the Pancreas

United States, Spain, Hungary, France, Portugal, Korea, Republic of, Germany, United Kingdom, Austria, Italy, Israel, Australia, Brazil, Czechia, Belgium, Russian Federation, Canada, Greece
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

United States, Australia, Brazil, Chile, China, France, Germany, Guatemala, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer

Adenocarcinoma of the Rectum | Stage II Rectal Cancer | Stage III Rectal Cancer

United States, Canada, Puerto Rico, Peru

Clinical Trials on Siewert Type II Adenocarcinoma of Esophagogastric Junction in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations